In a novel series of DPP-IV inhibitors, a large increase of inhibitory activity was achieved by optimisation of aromatic substituents and conformational restriction. (C) 2004 Elsevier Ltd. All rights reserved.
In a novel series of DPP-IV inhibitors, a large increase of inhibitory activity was achieved by optimisation of aromatic substituents and conformational restriction. (C) 2004 Elsevier Ltd. All rights reserved.
The present invention provides compounds of formula (I)
1
wherein R
1
, R
2
, R
3
and R
4
are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
[EN] NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE PYRIDINE ET DE QUINOLINE
申请人:——
公开号:WO2003068748A9
公开(公告)日:2004-10-07
[EN] The present invention relates to compounds of formula (I), wherein R, R<2>, R<3> and R<4 >are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance. [FR] L'invention concerne des composés de formule générale (I), dans laquelle R, R<2>, R<3> et R<4 >ont la signification indiquée dans la description et dans les revendications, ainsi que des sels pharmaceutiquement acceptables de ceux-ci. Ces composés sont utiles dans le traitement et/ou la prophylaxie de maladies associées au DPP IV, de type diabète, en particulier le diabète insulino-dépendant, et la diminution de la tolérance au glucose.
In a novel series of DPP-IV inhibitors, a large increase of inhibitory activity was achieved by optimisation of aromatic substituents and conformational restriction. (C) 2004 Elsevier Ltd. All rights reserved.